But in combination, MDM2 plus BRAF inhibition (Figure 6A) and MDM2 plus MEK inhibition (Figure 6B) elicited 89 and 93% decreases in tumor volume, respectively (p < 0.0001 for each combination vs. its respective single-agent comparators). Here, BRAF is linked to neoplasm.